Dutasteride not a cost-effective way to prevent prostate cancer in some men

	Tweet

The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease, according to findings by a UT Southwestern Medical Center researcher.

In a study available in the January issue of Cancer Prevention Research, investigators found that the medication, at an annual cost of $1,400, is impractical when compared to the marginal impact on survival and quality of life in at-risk groups. The drug is indicated for the treatment of enlarged prostates but also is widely prescribed for chemoprevention.

“Because prostate cancer is the most common cancer in men, the implications of this data are significant since there could be millions of men who would be eligible for anti-cancer drugs,” said Dr. Yair Lotan, associate professor of urology at UT Southwestern. “Prior to instituting a chemoprevention strategy to a large population, the utility and cost need to be well understood. Whether a medication improves survival, how it affects quality of life, and what its financial implications will be are all critical issues. Because dutasteride typically is prescribed for the lifetime of the patient, and therefore taken daily for decades, the cost issue is particularly relevant.”

Prior research has shown that dutasteride reduced the relative risk of prostate cancer over a four-year period by 22.8 percent, but questions have remained about its cost-effectiveness. The current study analyzed the lifetime health-related costs of the drug in patients at greater risk of developing prostate cancer and compared them to other factors, such as quality and length of life.

Dr. Lotan and his colleague, Dr. Robert Svatek of UT Health Science Center at San Antonio, used a Markov probability model to compare the lifetime cost of taking dutasteride with no therapy. They used data from a previous trial and studies that evaluated outcomes of patients with prostate cancer, including treatment-related complications to create the model. The primary outcome was measured in quality-adjusted life years (QALY), which takes into account both quality and quantity of life.

“The study found that dutasteride was not cost-effective for chemoprevention unless and until a strategy is developed for targeting very high-risk patients and the cost of the drug decreases,” said Dr. Lotan. “For the average man, the drug provides minimal survival benefits, and the reduction on treatment-related complications does not compensate for the high costs of every man taking the drug for many years.”

###

Visit http://www.utsouthwestern.org/urology to learn more about clinical services in urology at UT Southwestern.

###

Contact: Rachel Skei Donihoo

214-648-3404
UT Southwestern Medical Center

RELATED STORIES:
Drug Shows Activity in Men with Advanced Prostate Cancer   Prostate Cancer Clinical Findings   Scientists see progress in prostate cancer tests   Closely monitoring low-risk prostate cancer, with biopsy, does not raise risk of death   Pomegranate juice helps fight prostate cancer   Androgen deprivation therapy does not prevent prostate cancer from spreading   Hormonal Dietary Supplements Might Promote Prostate Cancer Progression   Vaccine Approach Extends Life of Metastatic Prostate Cancer Patients   Gene Fusion Discovery May Lead to Improved Prostate Cancer Test   Mushroom extract may boost prostate cancer drug   Prostate cancer spurs new nerves   Drug shows promise in prostate cancer spread to bone   What is the role of focal therapy in low-risk prostate cancer?   Folic Acid Supplements Linked To Higher Risk Of Prostate Cancer   Heavy men fare poorly with prostate cancer   Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians   Study links obesity to more agressive prostate cancer   New Web site Helps Doctors and Prostate Cancer Patients Make Better Treatment Choices   Radiation added to hormone therapy increases survival for men with prostate cancer   Standard Treatment for Prostate Cancer May Encourage Spread of Disease   Younger men do well with prostate cancer surgery   Mediterranean Diet May Help Prevent Prostate Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]